NCT04904302 2026-03-16Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerM.D. Anderson Cancer CenterPhase 2 Terminated15 enrolled
NCT03606174 2023-08-24A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaMirati Therapeutics Inc.Phase 2 Terminated260 enrolled 28 charts